Prosecution Insights
Last updated: November 08, 2026
Application No. 19/377,742

SYSTEMS AND METHODS FOR PROCESSING OF FUNDUS IMAGES

Final Rejection §102§103§112
Filed
Nov 03, 2025
Priority
Nov 01, 2024 — provisional 63/715,370
Examiner
LI, JOHN DENNY
Art Unit
3798
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Toku Eyes Limited
OA Round
2 (Final)
64%
Grant Probability
Moderate
3-4
OA Rounds
2y 3m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 64% of resolved cases
64%
Career Allowance Rate
172 granted / 270 resolved
-6.3% vs TC avg
Strong +48% interview lift
Without
With
+48.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
43 currently pending
Career history
315
Total Applications
across all art units

Statute-Specific Performance

§101
6.3%
-33.7% vs TC avg
§103
48.0%
+8.0% vs TC avg
§102
12.5%
-27.5% vs TC avg
§112
30.4%
-9.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 270 resolved cases

Office Action

§102 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-17 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claim 1, the claim recites an indication of risk of CKD twice. The second instance of an indication of risk has unclear antecedent basis. It is unclear how this indication of risk relates to the indication of risk set forth earlier in the claim. For examination purposes, this limitation will be interpreted as referring to the indication of risk set forth earlier in the claim and reciting “the” indication of risk. Regarding claim 9, the claim recites an indication of risk of CKD twice. The second instance of an indication of risk has unclear antecedent basis. It is unclear how this indication of risk relates to the indication of risk set forth earlier in the claim. For examination purposes, this limitation will be interpreted as referring to the indication of risk set forth earlier in the claim and reciting “the” indication of risk. Regarding claim 17, the claim recites an indication of risk of CKD twice. The second instance of an indication of risk has unclear antecedent basis. It is unclear how this indication of risk relates to the indication of risk set forth earlier in the claim. For examination purposes, this limitation will be interpreted as referring to the indication of risk set forth earlier in the claim and reciting “the” indication of risk. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1-3, 5-11, and 13-17 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Zhang et al. (WO2022261513, hereafter Zhang). Regarding claims 1, 9, and 17, Zhang discloses a method of determining an indication of risk of chronic kidney disease (CKD) of an individual (Zhang, Pg 3; “In one aspect, the present disclosure provides a method comprising using at least one computer processor to: receive one or more retinal fundus images of a patient; apply a machine-learning classifier having been trained using a dataset of retinal fundus images of a patient cohort that have been classified regarding a chronic kidney disease (CKD) status, to classify the received one or more fundus images of the patient to thereby diagnose whether the patient has CKD. The diagnosis result can then be provided to a user in a user readable form”), a system comprising: a memory storing program instructions; and at least one processor configured to execute program instructions stored in the memory, wherein the program instructions cause the processor to perform a method of determining an indication of risk of chronic kidney disease (CKD) of an individual (Zhang, Pg 4; “In another aspect, the present disclosure provides a system or device including at least one processor, a memory, and non-transitory computer readable storage media encoded with a program including instructions executable by the at least one processor and cause the at least one processor to perform the methods described herein.”), and a computer program product, the computer program product comprising: a non-transitory computer-readable medium having computer-readable program code stored thereon, the computer-readable program code comprising instructions that when executed by a processor, cause the processor to perform a method of determining an indication of risk of chronic kidney disease (CKD) of an individual (Zhang, Pg 4; “In another aspect, the present disclosure provides a non-transitory computer readable medium encoded with a program including instructions executable by at least one processor and cause the at least one processor to perform the methods described herein.”), comprising: determining an indication of risk of chronic kidney disease (CKD) (Zhang, Pg 3; “receive one or more retinal fundus images of a patient; apply a machine-learning classifier having been trained using a dataset of retinal fundus images of a patient cohort that have been classified regarding a chronic kidney disease (CKD) status, to classify the received one or more fundus images of the patient to thereby diagnose whether the patient has CKD. The diagnosis result can then be provided to a user in a user readable form”) by a deep learning model (Zhang, Pg 4; “the methods further comprises classifying the patient as belonging to one of a plurality categories having different risks for developing CKD in the future, such as low-risk, medium-risk, and high-risk […] the machine-learning classifier comprises a deep learning model. The deep learning model can comprise convolutional neural networks (CNN).”) based on one or more fundus images (Zhang, Pg 3; “apply a machine-learning classifier having been trained using a dataset of retinal fundus images of a patient cohort that have been classified regarding a chronic kidney disease (CKD) status”). Regarding claims 2 and 10, Zhang discloses all of the limitations of claims 1 and 9 as discussed above. Zhang further discloses wherein the deep learning model comprises a plurality of retinal predictor models, and the method comprises processing the one or more fundus images using the plurality of retinal predictor models and outputting at least one feature from each of the retinal predictor models (Zhang, Pg 2; “Here we explored risk stratification for developing CKD and T2DM using both retinal images and known clinical risk factors.”) (Zhang, Pg 11; “Figure 3. Model performance in assessing eGFR from retinal fundus images. a–c, Correlation analysis of the predicted GFR versus actual eGFR generated using the regression model”) (Zhang, Pg 18; “For regression tasks, we trained two models to predict continuous values of eGFR and fasting blood glucose, respectively. The detection of systemic disease or staging was treated as a classification task. We also performed binary classification for T2DM detection.”) (Zhang, Pg 13; “Comparison of the AI’s performance at detecting T2DM patients with images with no apparent signs of diabetic retinopathy (NDR) and images with diabetic retinopathy (DR).”) (Zhang, Pg 12; “Gradient visualizations of AI predictions of CKD staging and T2DM using the integrated gradient algorithm.”). Regarding claims 3 and 11, Zhang discloses all of the limitations of claims 2 and 10 as discussed above. Zhang further discloses wherein the plurality of retinal predictor models are configured to output at least two of the following features: Estimated Glomerular Filtration Rate (eGFR), Albumin-to-Creatinine Ratio (ACR), Systolic Blood Pressure (SBP), Retinopathy grade, and Maculopathy grade (Zhang, Pg 2; “Here we explored risk stratification for developing CKD and T2DM using both retinal images and known clinical risk factors.”) (Zhang, Pg 11; “Figure 3. Model performance in assessing eGFR from retinal fundus images. a–c, Correlation analysis of the predicted GFR versus actual eGFR generated using the regression model”) (Zhang, Pg 18; “For regression tasks, we trained two models to predict continuous values of eGFR and fasting blood glucose, respectively. The detection of systemic disease or staging was treated as a classification task. We also performed binary classification for T2DM detection.”) (Zhang, Pg 13; “Comparison of the AI’s performance at detecting T2DM patients with images with no apparent signs of diabetic retinopathy (NDR) and images with diabetic retinopathy (DR).”) (Zhang, Pg 12; “Gradient visualizations of AI predictions of CKD staging and T2DM using the integrated gradient algorithm.”). Regarding claims 5 and 13, Zhang discloses all of the limitations of claims 2 and 10 as discussed above. Zhang further discloses wherein the deep learning model comprises at least one CKD risk prediction model, and the method comprises processing the features output by the plurality of retinal predictor models using the at least one CKD risk prediction model to determine the indication of risk of chronic kidney disease (CKD) (Zhang, Pg 17; “The following criteria were used to define systemic disease and related disease staging. According to the international kidney disease clinical classification based on the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline, the staging and actual risk of adverse outcomes of kidney disease are stratified by the renal glomerular filtration function defined as the GFR categories [33]. , which equals the total amount of fluid filtered through the functioning nephrons per unit of time [34]. The Estimated Glomerular Filtration Rate (eGFR) in this study was based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Equation.”) Regarding claims 6 and 14, Zhang discloses all of the limitations of claims 5 and 13 as discussed above. Zhang further discloses wherein the deep learning model comprises at least one CKD risk prediction model, and the method comprises processing the features output by the plurality of retinal predictor models using the at least one CKD risk prediction model to determine the indication of risk of chronic kidney disease (CKD) (Zhang, Pg 17; “The following criteria were used to define systemic disease and related disease staging. According to the international kidney disease clinical classification based on the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline, the staging and actual risk of adverse outcomes of kidney disease are stratified by the renal glomerular filtration function defined as the GFR categories [33]. , which equals the total amount of fluid filtered through the functioning nephrons per unit of time [34]. The Estimated Glomerular Filtration Rate (eGFR) in this study was based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Equation.”). Regarding claims 7 and 15, Zhang discloses all of the limitations of claims 5 and 13 as discussed above. Zhang further discloses wherein the at least one CKD risk prediction model comprises a plurality of CKD risk prediction models, and weighted outputs of the plurality of CKD risk prediction models contribute to determining the indication of risk of chronic kidney disease (CKD) (Zhang, 10; “Figure 2. Performance of the AI models in the identification of CKD and early CKD. ROC curves represent the metadata-only model, the fundus-only model and the combined model”) (Zhang, Pg 12; “Four types of fundus images after the application of color normalization and CLAHE image enhancements: original image, image after applying the CLAHE transformation only, image after applying the color normalization transformation only, and image after applying both the CLAHE and color normalization transformations. Each image instance separately makes a prediction, and these are combined by averaging the results for producing a robust AI model.”) (Zhang, Pg 22; “The univariable and multivariable CPH models were fitted. Two multivariable CPH models were developed, a combined metadata and fundus model and a metadata-only model serving as a baseline model. Statistical significance of HRs and adjusted HRs of CPH models were evaluated using the likelihood ratio test.”). Regarding claims 8 and 16, Zhang discloses all of the limitations of claims 5 and 13 as discussed above. Zhang further discloses wherein the method comprises inputting at least one patient demographic into the at least one CKD risk prediction model, wherein the at least one patient demographic comprises one or more of: Age, Gender, diabetic status, race and/or ethnicity, smoking status, CVD history, and hypertension medications (Zhang, Pg 4; “the machine-learning classifier further utilizes clinical metadata of the patient, and wherein the machine-learning classifier has been trained using a Cox proportional hazards (CPH) model based on the dataset of retinal fundus images of each of the patients in the cohort in combination with clinical metadata of each of the patients in the cohort. The clinical metadata of a patient can include one or more of the following: age, sex, blood pressure, height, weight, BMI, and hypertension status”). Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 4 and 12 are rejected under 35 U.S.C. 103 as being unpatentable over Zhang and Bergman et al. (US20210038165, hereafter Bergman). Regarding claims 4 and 12, Zhang discloses all of the limitations of claims 3 and 11 as discussed above. Zhang does not clearly and explicitly disclose wherein the plurality of retinal predictor models are further configured to output at least one of the following features: race and/or ethnicity, Total Cholesterol, Retinal Age, Smoking status, and a cardiovascular disease (CVD) risk biomarker velocity. In an analogous CKD analysis using retinal images field of endeavor Bergman discloses outputting at least one of the following features: race and/or ethnicity, Total Cholesterol, Retinal Age, Smoking status, and a cardiovascular disease (CVD) risk biomarker velocity (Bergman, Para 72; “if the computer processors 110 detect that a user is at risk of having or developing CKD, the computer processors 110 can cause the alert module 107 to generate a print-out […] the print-out also lists the risk factors that lead to the determination (e.g., high BMI, albumin in urine, frequent smoking, etc.). As indicated earlier, this alert can be alternatively (or additionally) be provided by the user interface 104”). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify Zhang wherein the plurality of retinal predictor models are further configured to output at least one of the following features: race and/or ethnicity, Total Cholesterol, Retinal Age, Smoking status, and a cardiovascular disease (CVD) risk biomarker velocity in order to allow a user to determine the correct healthcare professional or treatment needed to address the potential health issue as taught by Bergman (Bergman, Para 72). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to John Li whose telephone number is (313)446-4916. The examiner can normally be reached Monday to Thursday; 5:30 AM to 3:30 PM Eastern. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Pascal Bui-Pho can be reached at (571) 272-2714. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JOHN D LI/Primary Examiner, Art Unit 3798
Read full office action

Prosecution Timeline

Nov 03, 2025
Application Filed
Jul 07, 2026
Non-Final Rejection mailed — §102, §103, §112
Oct 06, 2026
Response Filed
Nov 06, 2026
Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12765912
DEVICE AND METHOD FOR AUTOMATED INSERTION OF PENETRATING MEMBER
2y 12m to grant Granted Oct 20, 2026
Patent 12766366
SYSTEM FOR PROVIDING GUIDED AND MONITORED EXERCISE ROUTINES
1y 9m to grant Granted Oct 20, 2026
Patent 12733907
Transducer Array Device, Method and System for Cardiac Conditions
2y 10m to grant Granted Sep 15, 2026
Patent 12727859
METHOD AND APPARATUS FOR PERFORMING SPECTRAL DOPPLER IMAGING
3y 5m to grant Granted Sep 08, 2026
Patent 12721590
Closed-Loop Control of Heart Failure Interventional Therapy
4y 5m to grant Granted Sep 01, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
64%
Grant Probability
99%
With Interview (+48.0%)
3y 3m (~2y 3m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 270 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month